Stock AnalizWest Pharmaceutical Services Inc. WST
Medical/Dental Instruments · data as of November 13, 2026
West Pharmaceutical Services Inc. (WST) is a healthcare company listed in the US with a market value of about $29.0B. In the twelve months to September 30, 2026 it had revenue of $3.4B and net income of $639M, a net margin of 18.8%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 46.7, a price to free cash flow of 64.0, 5-year revenue growth of 7% a year, a 5-year average ROIC of 18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 71% below the current price.
Score: 2.6 / 5
Checks passed
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.1B | $2.9B | $2.9B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B |
| Net income | $639M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M |
| Free cash flow | $453M | $469M | $276M | $414M | $439M | $331M | $298M | $241M | $184M | $132M | $49M |
| EPS (diluted) | $8.91 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
| Net margin | 18.8% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% |
| ROIC | — | 13.3% | 15.6% | 17.5% | 20.3% | 24.2% | 15.3% | 12.4% | 12.5% | 9.7% | 10.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $471.00, 13% above the current price; targets range from $340.00 to $500.00; the consensus rating is “Strong buy”; expected EPS is $9.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is West Pharmaceutical Services’s P/E ratio?
About 46.7, based on the last twelve months of diluted earnings per share (forward P/E about 42.4).
Is West Pharmaceutical Services stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 71% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does West Pharmaceutical Services pay a dividend?
Yes. The dividend yield is about 0.25%, and it has paid dividends for 10 years in our data.
Is West Pharmaceutical Services a good stock to buy?
We do not give buy or sell advice. West Pharmaceutical Services scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.